Access · International · continued

[2026 update] Travelling with an injectable: documentation and practicalities posts 91–112

Access › International telehealth EMA MHRA NHS

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

hana.satoTL4 Moderator18 Jul 2026#91

NLoughran, post #55: Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk. Old habit: I write down the expected answer before I calculate it. Go to post

Post #90 is the version of this I will quote in future. One addition.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

2 likes in reply to #55 9d

c.ostergaardTL219 Jul 2026#92

Where I part company with post #88, and it is a narrow parting.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

8 likes 9d

p.iyer_pharmdTL3Pharmacist19 Jul 2026#93

Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.

That is a description of practice, not a recommendation of it.

27 likes 9d

h.iyerTL220 Jul 2026#94

Collapsed as off-topic by two members at trust level 3 or above

Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.

Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.

blank_injectionTL2Analytical chemist20 Jul 2026 · edited#95

d.ndiaye, post #67: Everything in post #65 holds. The case it does not cover is the one I have. The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them. Not disagreeing with anyone above, just adding the bit I keep having to look up. Go to post

Confirming post #93 from a second method, which matters more than confirming it from a second person.

Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.

0 likes in reply to #67 8d

n.villalobosTL220 Jul 2026#96

c.castellanos, post #89: Where I part company with post #87, and it is a narrow parting. Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging. Filing this under things that are true until someone shows me otherwise. Go to post

A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.

I have kept the units in throughout, for the obvious reason.

5 likes in reply to #89 7d

forest_plotTL3Evidence synthesis21 Jul 2026#97

Marking my place. If it changes for me I will come back and say so.

20 likes 7d

s.antonsenTL221 Jul 2026#98

Post #96 describes the usual case. This is about the unusual one.

Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.

0 likes 7d

a.sorensenTL222 Jul 2026#99

Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging.

It is the sort of thing that seems obvious in retrospect and was not at the time.

0 likes 6d

s.duarteTL222 Jul 2026#100

w.moreau, post #61: Travelling with a prescribed medicine is a documentation question and the requirements are published by the destination rather than the origin. Go to post

Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).

That has been true for the cases I have seen and I have not seen many.

2 likes in reply to #61 6d

e.steinerTL222 Jul 2026#101

Post #100 answers the question as asked. The question underneath it is different.

Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.

Someone will know this better than I do and I hope they say so.

2 likes 6d

tracked_parcelTL2Regular23 Jul 2026#102

f.wojcik, post #42: Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question. Small point, but it is the one that usually catches people. Go to post

Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.

8 likes in reply to #42 5d

r.vukovicTL223 Jul 2026#103

j.vandermolen, post #76: Clear enough that I do not think I have a follow-up, which is unusual. Go to post

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

19 likes in reply to #76 5d

unit_conversionTL3Regular23 Jul 2026#104

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

Worth checking against a second source before it gets quoted onward.

0 likes 4d

m.balogunTL224 Jul 2026#105

The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.

0 likes 4d

p.novotnyTL2Regular24 Jul 2026#106

Travelling with a prescribed medicine is a documentation question and the requirements are published by the destination rather than the origin.

4 likes 4d

f.haddadTL225 Jul 2026#107

Collapsed as off-topic by two members at trust level 3 or above

Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.

Anyone who has looked at this more carefully, please correct the record.

eire_readerTL2Regional · IE25 Jul 2026 · edited#108

That is consistent with mine, for whatever one more account is worth.

27 likes 3d

ai.vukovicTL225 Jul 2026#109

p.novotny, post #106: Travelling with a prescribed medicine is a documentation question and the requirements are published by the destination rather than the origin. Go to post

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

The general case is well covered; this is the awkward specific one.

0 likes in reply to #106 3d

WendelboeTL226 Jul 2026#110

Collapsed as off-topic by two members at trust level 3 or above

Answering the question post #106 raises rather than the one it answers.

The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.

The right answer here may simply be that it has not been measured.

bench_peakTL3Regular26 Jul 2026#111

Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.

0 likes 2d

r.coelhoTL226 Jul 2026 · edited#112

The arithmetic in post #109 is right; the assumption feeding it is the part to check.

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

That is all I can say without guessing.

0 likes 1d

Topic	Participants	Replies	Views	Activity
Personal import allowances, compared — a second dataset Access › International personal import telehealth MHRA EMA Wiki Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Personal import allowances. It is mine, it is…	+124	132	9.2k	2mo
What changed in 2026, by region — does this still hold? Access › International personal import MHRA EMA telehealth Solved What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…	+20	25	50k	1d
Prescription portability between countries Access › International personal import MHRA telehealth EMA Wiki Prescription portability between countries — setting out what I have, and where I think it stops being reliable. Asking about prescription portability between countries directly, because I have read four…	+104	114	6.1k	3h
What changed in 2026, by region Access › International EMA NHS personal import Solved What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…	+110	122	1.4k	18mo
[2026 update] Availability by country, dated, with primary sources Access › International MHRA NHS telehealth personal import On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…	+40	45	14k	4mo

Topic	Participants	Replies	Views	Activity
Travelling with an injectable: documentation and practicalities Access › International NHS personal import EMA MHRA Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting a stated criterion rather than an outcome,…	+37	42	2.1k	1d
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says,…	+36	40	37k	11mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…	+46	50	7.9k	5mo
Coming back to: Getting a referral rather than a refusal Clinical › Prescriber conversations prior authorisation telehealth type 2 diabetes beginner friendly Solved Posting this under the heading it deserves: Getting a referral rather than a refusal Everything below is what sits behind that. Working notes on Getting a referral rather than a conclusion. I would rather…	+69	74	1.7k	13mo
Pharmaceutical compounding rules, summarised from primary sources Sourcing › Regulatory MHRA EMA research use only Closed Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of…	+135	163	46k	17mo

[2026 update] Travelling with an injectable: documentation and practicalities posts 91–112

Suggested topics

Related topics — sharing the tags telehealth, EMA, MHRA